Scientists are increasingly investigating retatrutide, a innovative drug from Eli Lilly, as a potential advance in body reduction . Unlike many earlier approaches, retatrutide is a twin-action agonist targeting both GLP-1 and GIP, chemicals that impact appetite and blood sugar regulation . Early